INmune Bio Inc Dossier
Qualitative Analysis
Business overview
INmune Bio, Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing immunotherapies that reprogram the patient's innate immune system to fight neurodegenerative diseases, oncology, and chronic inflammation. The company's pipeline is built around three core product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform (featuring lead candidate XPro1595/XPro™ for early Alzheimer's disease), the CORDStrom™ mesenchymal stromal cell platform (targeting Recessive Dystrophic Epidermolysis Bulosa), and the INKmune® natural killer (NK) cell-priming platform for oncology. Unlike traditional therapies targeting the adaptive immune system or amyloid-beta plaques, INmune Bio focuses on targeting soluble TNF to reduce neuroinflammation and prime innate immune cells.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a mid-stage clinical developer to a late-stage, registration-directed organization by advancing CORDStrom™ for Recessive Dystrophic Epidermolysis Bullosa (RDEB) toward global regulatory filings.
Expected impact: Achieving commercial-stage status and potential monetization of a Priority Review Voucher.
Advancing XPro™ in early Alzheimer's Disease using an integrated Phase 2b/3 registrational pathway aligned with the FDA, focusing on patients with neuroinflammation biomarkers.
Expected impact: De-risking clinical trial design and targeting objective neuroinflammation biomarkers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio's CORDStrom™ platform, supporting global regulatory compliance (FDA, EMA, MHRA) and expanding clinical targets to oncology and inflammatory diseases.
Terms: Anthony Nolan will receive a 2% royalty on net sales per Product, capped at £5,000,000 annually, plus £400 per umbilical cord tissue for Cell and Gene Therapies Services, with annual CPI-linked fee increases starting January 1, 2027.